NASDAQ
KLRS
Last Price
US $4.07
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Kalaris Therapeutics Inc cash flow to debt ratio of -2.97K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
Kalaris Therapeutics Inc's free cash flow has increased -36.23% from $-67.70M last year to $-43.18M, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
Kalaris Therapeutics Inc's debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial risk - Healthy debt to equity ratio development.
Kalaris Therapeutics Inc has insufficient data to evaluate this check.
Financial risk - Net debt/EBITDA.
Kalaris Therapeutics Inc has negative EBITDA, making leverage ratio unreliable
Financial risk - ICR.
Kalaris Therapeutics Inc interest expense data unavailable for the most recent period; interest coverage ratio cannot be reliably computed.
Financial risk - Profit margin growth.
Kalaris Therapeutics Inc has insufficient data to evaluate this check.
Financial stability - Short term assets vs short term liabilities.
Kalaris Therapeutics Inc's short-term assets of $118.81M exceed its short-term liabilities of $9.71M
Decreasing performance - ROA.
Kalaris Therapeutics Inc's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Kalaris Therapeutics Inc's return on equity of -72.78%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Kalaris Therapeutics Inc's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Kalaris Therapeutics Inc had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Kalaris Therapeutics Inc has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Kalaris Therapeutics Inc has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Kalaris Therapeutics Inc's yearly earnings has increased -26.09% since last year from $-58.77M to $-43.44M, signaling increasing performance
Increasing performance - Healthy revenue growth.
Kalaris Therapeutics Inc's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance
Decreasing performance - ROIC.
ROIC -46.68% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Kalaris Therapeutics Inc has insufficient revenue history to calculate 3-year revenue CAGR.
Increasing performance - Revenue consistency.
Kalaris Therapeutics Inc had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Kalaris Therapeutics Inc had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Kalaris Therapeutics Inc has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Kalaris Therapeutics Inc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Kalaris Therapeutics Inc is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Kalaris Therapeutics Inc has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Kalaris Therapeutics Inc has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Kalaris Therapeutics Inc has a price-to-book ratio of 1.49x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
Kalaris Therapeutics Inc has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-72.78%
Return on equity
ROIC: -46.68%
Valuation History
-2.0X
Price to Earnings
EV/EBITDA: -1.1X
Cash flow
Profit margin
10.67%
(FY vs FY)
Cash flow Y/Y
7.17%
(FY vs FY)
Fair Value
Market $4.07
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.